Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 Mice

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Antisense and Nucleic Acid Drug Development

• Publication date

  1997-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/oli.1.1997.7.473PMID 9361906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.

  1997influential reference
• Progress in antisense therapeutics.

  1996cited by this paper
• CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.

  1996cited by this paper
• Activation of human B cells by phosphorothioate oligodeoxynucleotides.

  1996cited by this paper
• Progress in antisense oligonucleotide therapeutics.

  1996cited by this paper
• Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides

  1995cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper
• Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities.

  1994influential reference
• In Vivo Toxicological Effects of rel A Antisense Phosphorothioates in CD-1 Mice

  1994influential reference
• Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus.

  1994cited by this paper
• Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides.

  1994cited by this paper
• Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

  1993cited by this paper
• Stimulation ofin vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides

  1993cited by this paper
• Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1.

  1993cited by this paper
• Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.

  1993cited by this paper
• Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1.

  1993cited by this paper
• Endothelial-leukocyte adhesion molecules.

  1993influential reference
• A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-κ-B Causes Sequence-Specific Immune Stimulation

  1993cited by this paper
• In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts.

  1990cited by this paper
• Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

  1988cited by this paper
• DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA.

  1985cited by this paper
• Specific binding of poly(I) · poly(C) to the membrane of murine B lymphocyte subsets

  1978cited by this paper
• An integrated and comparative study of the antiviral effects and other biological properties of the polyinosinic-polycytidylic acid duplex and its mismatched analogues. III. Chronic effects and immunological features.

  1976cited by this paper
• Stimulation of humoral antibody formation by polyanions. I. The effect of polyacrylic acid on the primary immune response in mice immunized with sheep red blood cells

  1971cited by this paper
• Systemic toxicity of polyinosinic acid: polycytidylic acid in rodents and dogs.

  1971cited by this paper
• Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice

  1971cited by this paper
• Antisense Oligonucleotides as Therapeutic Agents Is the Bullet Really Magical ?

  year unknowncited by this paper

• Developing splice-switching oligonucleotides for urea cycle disorder using an integrated diagnostic and therapeutic platform.

  2025cites this paper
• Advancements in SELEX Technology for Aptamers and Emerging Applications in Therapeutics and Drug Delivery

  2025cites this paper
• Stargardt disease-associated in-frame ABCA4 exon 17 skipping results in significant ABCA4 function

  2023cites this paper
• Aptamer: A Theranostic Approach Towards Breast Cancer

  2023cites this paper
• Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond

  2022cites this paper
• Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future

  2020cites this paper
• Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors

  2020cites this paper
• Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future.

  2019cites this paper
• Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties

  2019cites this paper
• Toxicologic evaluation of repetitive 4‐week intravenous injections of midkine antisense oligonucleotide nanoliposomes in rats

  2019cites this paper
• Chronic Toxicity Assessment of 2′-O-Methoxyethyl Antisense Oligonucleotides in Mice

  2018cites this paper
• Aptamer Therapeutics in Cancer: Current and Future

  2018cites this paper
• Hybridization-Independent Effects

  2018cites this paper
• Class-Related Proinflammatory Effects

  2018cites this paper
• Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia

  2017cites this paper
• Oligonucleotide‐based pharmaceuticals: Non‐clinical and clinical safety signals and non‐clinical testing strategies

  2017cites this paper
• E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases.

  2016cites this paper
• E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases.

  2016cites this paper
• Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics

  2015cites this paper
• Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer

  2015cites this paper
• Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts

  2015cites this paper
• Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice.

  2015cites this paper
• Synergistic Effects of Combining Anti-Midkine and Hepatocyte Growth Factor Therapies Against Diabetic Nephropathy in Rats

  2015cites this paper
• Mechanism of Alternative Complement Pathway Dysregulation by a Phosphorothioate Oligonucleotide in Monkey and Human Serum

  2014cites this paper
• Phosphorothioate oligonucleotides: effectiveness and toxicity.

  2014cites this paper
• Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys

  2013influential citation
• A Locked Nucleic Acid Oligonucleotide Targeting MicroRNA 122 Is Well-Tolerated in Cynomolgus Monkeys

  2012influential citation
• Therapeutic Applications of Synthetic CpG Oligodeoxynucleotides as TLR9 Agonists for Immune Modulation

  2012cites this paper
• Pharmacokinetics and Toxicity in Rats and Monkeys of coDbait: A Therapeutic Double-stranded DNA Oligonucleotide Conjugated to Cholesterol

  2012cites this paper
• Unique O-Methoxyethyl Ribose-DNA Chimeric Oligonucleotide Induces an Atypical Melanoma Differentiation-Associated Gene 5-Dependent Induction of Type I Interferon Response

  2012cites this paper
• Safety Assessment Studies: Immunotoxicity

  2010cites this paper
• Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers

  2009cites this paper
• Clinical Development of Oligodeoxynucleotide TLR9 Agonists

  2008cites this paper
• Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors

  2008cites this paper
• Antiinfective applications of toll-like receptor 9 agonists.

  2007cites this paper
• Brief Communication: Stability and Catalytic Activity of Novel Circular DNAzymes

  2006cites this paper
• Assessment of the Effects of ISIS 2302, an Anti-Sense Inhibitor of Human ICAM-1, on Cellular and Humoral Immunity in Mice

  2006cites this paper
• Therapeutic potential of Toll-like receptor 9 activation

  2006cites this paper
• CpG and Non-CpG Oligodeoxynucleotides Induce Differential Proinflammatory Gene Expression Profiles in Liver and Peripheral Blood Leukocytes in Mice

  2006cites this paper
• Methods of evaluating immunotoxicity

  2006cites this paper
• Antisense oligonucleotides as therapeutics for hyperlipidaemias

  2005cites this paper
• Immunotoxicology

  2005cites this paper
• Technology evaluation: alicaforsen (Isis).

  2005cites this paper
• DNA drug design for cancer therapy.

  2005cites this paper
• Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion.

  2005cites this paper
• Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.

  2004cites this paper
• Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits.

  2004cites this paper
• A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

  2004cites this paper
• Progress in antisense technology.

  2004cites this paper
• Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications

  2003cites this paper
• Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes

  2003cites this paper
• NMR studies of DNA single strands and DNA:RNA hybrids with and without 1-propynylation at C5 of oligopyrimidines.

  2003cites this paper
• Renal gene transfer

  2003cites this paper
• On the pathophysiological significance of CD154/CD40-mediated leukocyte-endothelial cell interaction

  2003cites this paper
• Gene Therapy for Renal Disorders

  2002cites this paper
• Cellular Uptake, Distribution, and Stability of 10-23 Deoxyribozymes

  2002cites this paper
• Antisense: Progress Towards Gene-Directed Cancer Therapy

  2002cites this paper
• 5′-,3′-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine

  2002cites this paper
• Fomivirsen.

  2001cites this paper
• Novel therapies for chronic myelogenous leukemia.

  2001cites this paper
• Renal gene therapy.

  2001cites this paper
• Chemically modified oligonucleotides exhibit decreased immune stimulation in mice.

  2000influential citation
• Sensible use of antisense: how to use oligonucleotides as research tools.

  2000cites this paper
• Pharmacokinetics and In Vivo Effects of a Six-Base Phosphorothioate Oligodeoxynucleotide with Anticancer and Hematopoietic Activities in Swine

  2000cites this paper
• Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice

  2000cites this paper
• In Vivo Expression of Single-Stranded DNA in Mammalian Cells with DNA Enzyme Sequences Targeted to C-raf

  2000cites this paper
• Acute, multiple-dose, and genetic toxicology of AR177, an anti-HIV oligonucleotide.

  2000cites this paper
• Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor

  2000cites this paper
• Acute Toxicology and Pharmacokinetic Assessment of a Ribozyme (ANGIOZYME™) Targeting Vascular Endothelial Growth Factor Receptor mRNA in the Cynomolgus Monkey

  2000influential citation
• Progress in antisense technology: the end of the beginning.

  2000cites this paper
• Oligonucleotide-based drugs in the control of cytokine synthesis

  2000cites this paper
• Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic

  2000cites this paper
• Novel Therapeutics from Modern Biotechnology

  1999cites this paper
• A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.

  1999cites this paper
• Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.

  1999cites this paper
• Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1

  1999cites this paper
• Abstracts from the Third Annual NIH Symposium on Therapeutic Oligonucleotides

  1999cites this paper
• The 3rd Annual NIH Symposium on Therapeutic Oligonucleotides. Bethesda, Maryland, USA. December 4, 1998. Abstracts.

  1999cites this paper
• Synthetic Oligonucleotides: The Development of Antisense Therapeutics

  1999cites this paper
• Disease Modifying Treatments for Multiple Sclerosis

  1999cites this paper
• Preclinical development of antisense therapeutics

  1999cites this paper
• Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.

  1999cites this paper
• Antisense oligonucleotide therapeutics.

  1999cites this paper
• Properties of ISIS 2302, an Inhibitor of Intercellular Adhesion Molecule-1, in Humans

  1998cites this paper
• Basic Principles of Antisense Therapeutics

  1998cites this paper
• Toxicity of Oligodeoxynucleotide Therapeutic Agents

  1998cites this paper
• Pharmacokinetics, Tissue Distribution, and Safety of P-Ethoxy Oligonucleotides Incorporated in Liposomes

  1998cites this paper
• Antisense Research and Application

  1998cites this paper
• Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.

  1998cites this paper
• PHARMACOKINETICS, TISSUE DISTRIBUTION, OLIGONUCLEOTIDES INCORPORATED IN LIPOSOMES AND SAFETY OF P-ETHOXY

  1998cites this paper
• A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

  1998cites this paper
• Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

  1997cites this paper
• Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.

  1997cites this paper
• Advances in understanding the pharmacological properties of antisense oligonucleotides.

  1997cites this paper
• Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

  1997cites this paper